Edition:
United Kingdom

People: Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

8.38USD
9:00pm BST
Change (% chg)

$-0.04 (-0.48%)
Prev Close
$8.42
Open
$8.39
Day's High
$8.47
Day's Low
$8.23
Volume
130,160
Avg. Vol
439,834
52-wk High
$15.47
52-wk Low
$6.00

McDade, Mark 

Mr. Mark D. McDade is Independent Director of the Company. Mr. McDade has been a director of our company since August 2014. Mr. McDade currently serves as a founding partner of Qiming Venture Capital US, a venture capital fund focused on investments in healthcare technology companies in the United States. Prior to that, he served in various roles with UCB S.A., a biopharmaceutical company, including as Executive Vice President, Chief Operating Officer from February 2015 to October 2016, Executive Vice President, Established Brands, Solutions and Supply from February 2013 to February 2015, Executive Vice President, Global Operations from January 2009 to February 2013 and Executive Vice President, Corporate Strategy and Development from April 2008 to December 2008. From November 2002 until October 2007, Mr. McDade served as Chief Executive Officer and on the board of directors of PDL BioPharma, Inc., a holding and management company. From December 2000 until November 2002, Mr. McDade served as Chief Executive Officer of Signature BioScience Inc., a drug discovery company. Prior to that, he co-founded and served as Chief Operating Officer of Corixa Corporation, a biopharmaceutical company, from September 1994 until December 1998, and as President and Chief Operating Officer from January 1999 to November 2000. Previously, Mr. McDade was Chief Operating Officer of Boehringer Mannheim Therapeutics, the biopharmaceutical division of Corange Limited, and held numerous business development and general management positions at Sandoz Ltd (a division of Novartis International AG). He has served as chair of the board of directors of Aimmune Therapeutics, Inc., a publicly-traded biotechnology company, since May 2015. From April 2005 to July 2009, he served on the board of directors of Cytokinetics, Incorporated, a biotechnology company, and from July 2006 to December 2018, he served on the board of directors of Five Prime Therapeutics, Inc., a biotechnology company.

Basic Compensation

Total Annual Compensation, USD 87,875
Restricted Stock Award, USD 29,850
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 117,725

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Thomas Wiggans

4,371,180

Luis Pena

2,519,500

Andrew Guggenhime

2,360,030

Christopher Horan

2,358,110

Christopher Griffith

833,154

Lori Lyons-Williams

2,704,630
As Of  31 Dec 2018